MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
Biopharma MacroGenics, Inc. (NASDAQ: MGNX) announced that the final overall survival (OS) analysis did not demonstrate a statistically…
Browsing Tag